Skip to main content
David Vesole, MD, Oncology, Hackensack, NJ

DavidH.VesoleMDPhD

Oncology • Hackensack, NJ

Co-Chief, Myeloma Division; Director, Myeloma Research, John Theurer Cancer Center; Director, Myeloma Program, Medstar Georgetown University Hospital

Join to view full profile

Dr. Vesole is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vesole's full profile

Already have an account?

  • Office

    92 2nd St
    Hackensack, NJ 07601
    Phone+1 551-996-8704
    Fax+1 551-996-0582

Summary

  • David H. Vesole, MD, PhD, FACP
    Co-Director, Myeloma Division; Director, Myeloma Research
    John Theurer Cancer Center at Hackensack University Medical Center
    Professor of Medicine, Georgetown University
    Director, Multiple Myeloma Program

    David H. Vesole completed a medical degree at Northwestern University and a doctorate in immunology and microbiology at the Medical University of South Carolina. His postdoctoral training included a residency in internal medicine and a fellowship in Hematology and Oncology at University of Iowa Hospitals and Clinics. Dr. Vesole is Co-Director, Myeloma Division and Director, Myeloma research at the John Theurer Cancer Center at Hackensack University Medical Center. He is Professor of Medicine at Georgetown University where he is Director, Myeloma Program. Dr. Vesole previously was the Director, BMT Program Loyola University in Maywood, IL, an attending physician at St. Vincent's Comprehensive Cancer Center in New York and Professor of Medicine and Clinical Director of the Blood and Marrow Transplant Program at the Medical College of Wisconsin in Milwaukee, WI.

    Board certified in medical oncology and hematology and a Fellow of the American College of Physicians, Dr. Vesole is active in several professional organizations, including the American Society for Blood and Marrow Transplantation, the American Society of Clinical Oncology and the American Society of Hematology. He previously served as Co-chair of the Eastern Cooperative Oncology Group Myeloma Committee and the Center for International Blood and Marrow Transplant Research (CIBMTR) Plasma Cell Disorder Committee. He was on the Nominating Committee for the CIBMTR. He is a Foundation for the Accreditation of Cellular Therapy (FACT) inspector and serves on the Clinical Standards, Accreditation and Data Management Task Force Committees for FACT. He is a member of the International Myeloma Working Group.

Education & Training

  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1987 - 1990
  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1984 - 1987
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 1984

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2005 - 2027
  • MD State Medical License
    MD State Medical License 2018 - 2025
  • NJ State Medical License
    NJ State Medical License 2009 - 2025
  • DC State Medical License
    DC State Medical License 2012 - 2024
  • IL State Medical License
    IL State Medical License 1985 - 2011
  • WI State Medical License
    WI State Medical License 1996 - 2009
  • IA State Medical License
    IA State Medical License 1984 - 2005
  • American Board of Internal Medicine Internal Medicine
  • ABIMHematology
  • ABIMMedical Oncology
  • Join now to see all

Awards, Honors, & Recognition

  • Board Member Leukemia Lymphoma Society, New York
  • Inside Jersey Magazine Top Doctors Castle Connolly, 2010-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2010-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
    Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
  • Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...  
    Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature

Abstracts/Posters

  • Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Mu...
    David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)
    David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
    David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Recent Advancements and Future Directions in Frontline Treatment of Multiple Myeloma
    Recent Advancements and Future Directions in Frontline Treatment of Multiple MyelomaJuly 11th, 2022
  • John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual Conference
    John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual ConferenceDecember 9th, 2021
  • John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100
    John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100August 4th, 2017
  • Join now to see all

Committees

  • Member, ASCO Plasma Cell Educational Committee 2015 - Present
  • Member, ASCO Clinical Practice Guidelines Committee 2015 - Present
  • Nominating Committee, American Society of Blood and Marrow Transplant 2015 - Present
  • Data Audit Committee, Federation for The Accreditation of Cellular Therapy 2014 - Present
  • Accreditation Committee, Federation for The Accreditation of Cellular Therapy
  • Clinical Standards Committee, Federation for The Accreditation of Cellular Therapy
  • Scientific Advisory Committee, International Myeloma Foundation
  • Myeloma Committee, Blood and Marrow Transplant Clinical Trials Network

Professional Memberships

Dr. David Vesole, Dr. David Vesole, MD, Dr. D Vesole, Dr. David H. Vesole